Stifel initiates Guardant Health [GH] at Buy and sets price target at $175
Stifel launched its Guardant Health [GH] rating to the equivalent of Buy and assigned the price target of $175.0, in a research note dated 2021-01-11. That figure represents around a 22.49% premium from where the company’s shares closed on Friday. Some new analysts also started their coverage, with BTIG Research’s analysts assigning the shares to […]
